Skip to main content

Drug Interactions between Entadfi and terbutaline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

terbutaline tadalafil

Applies to: terbutaline and Entadfi (finasteride / tadalafil)

MONITOR: Coadministration with tadalafil may increase the plasma concentrations of ethinyl estradiol and/or terbutaline. The mechanism of the interaction has not been fully elucidated but may involve inhibition of gut sulphation by tadalafil. At steady-state, tadalafil (40 mg once daily) increased ethinyl estradiol systemic exposure (AUC) by 26% and peak plasma concentration (Cmax) by 70% compared to an oral contraceptive taken with placebo. A similar increase may be expected with oral administration of terbutaline. The clinical significance of these findings is unknown.

MANAGEMENT: Clinicians should consider the potential for interaction during concomitant administration of tadalafil with ethinyl estradiol and/or terbutaline. If coadministration is required, caution and clinical monitoring is advisable. Individual product labeling should be consulted for further guidance.

References (3)
  1. (2023) "Product Information. Adcirca (tadalafil)." Eli Lilly and Company Ltd
  2. (2024) "Product Information. Opsynvi 10/40 (macitentan-tadalafil)." Janssen-Cilag Pty Ltd
  3. (2025) "Product Information. Opsynvi (macitentan-tadalafil)." Janssen Inc

Drug and food/lifestyle interactions

Moderate

tadalafil food/lifestyle

Applies to: Entadfi (finasteride / tadalafil)

GENERALLY AVOID: Coadministration with grapefruit juice is likely to increase the plasma concentrations of tadalafil, which is primarily metabolized by CYP450 3A4. However, the interaction has not been studied. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.

MONITOR: Additive hypotensive effects may occur when phosphodiesterase-5 (PDE5) inhibitors such as tadalafil are used with alcohol, as both are mild systemic vasodilators. In clinical pharmacology studies, more subjects administered alcohol at a dose of 0.7 g/kg (equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male; consumed within 10 minutes in study subjects, providing blood alcohol levels of 0.08%) in combination with tadalafil 10 or 20 mg single doses had clinically significant decreases in blood pressure than with alcohol alone. There were reports of postural dizziness, and orthostatic hypotension was observed in some. When tadalafil 20 mg was administered with alcohol at a lower dose of 0.6 g/kg (equivalent to approximately 4 ounces of 80-proof vodka in an 80-kg male), orthostatic hypotension was not observed, dizziness occurred with similar frequency relative to alcohol alone, and the hypotensive effects of alcohol were not potentiated. Neither tadalafil nor alcohol affected the plasma concentrations of the other.

MANAGEMENT: Caution is recommended with concurrent consumption of large amounts of alcohol in patients taking tadalafil as it may increase the potential for orthostatic signs and symptoms, such as increase in heart rate, decrease in standing blood pressure, dizziness, and headache. It may also be appropriate to avoid consuming large amounts of grapefruit juice.

References (8)
  1. (2009) "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation
  2. (2024) "Product Information. Opsynvi (macitentan-tadalafil)." Actelion Pharmaceuticals US Inc
  3. (2023) "Product Information. Adcirca (tadalafil)." Eli Lilly and Company Ltd
  4. (2024) "Product Information. Opsynvi 10/40 (macitentan-tadalafil)." Janssen-Cilag Pty Ltd
  5. (2025) "Product Information. Opsynvi (macitentan-tadalafil)." Janssen Inc
  6. (2019) "Product Information. Tadalafil (tadalafil)." Amneal Pharmaceuticals LLC
  7. (2021) "Product Information. Ach-Tadalafil (tadalafil)." Accord Healthcare Inc
  8. (2024) "Product Information. Cialis (tadalafil)." Eli Lilly Australia Pty Ltd
Moderate

terbutaline food/lifestyle

Applies to: terbutaline

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.